ORIC Pharmaceuticals to Present Phase 1b Data on ORIC-944 with Androgen Receptor Inhibitors in mCRPC Patients

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2025 -- ORIC Pharmaceuticals, Inc., an oncology-focused clinical-stage company, has revealed plans to share initial findings from their Phase 1b study of ORIC-944, used alongside androgen receptor inhibitors, for patients facing metastatic castration-resistant prostate cancer (mCRPC). The details will be discussed in a conference call and webcast scheduled for Wednesday, May 28, 2025, at 4:30 p.m. ET. Interested participants are encouraged to pre-register online to obtain the necessary phone number and passcode. Additionally, the event will be streamed live via the investor section on ORIC's official website, where it will also be accessible for replay over the following 90 days.

ORIC-944 is distinguished as a potent and selective allosteric inhibitor targeting the polycomb repressive complex 2 (PRC2) through its interaction with the embryonic ectoderm development (EED) subunit. Initially assessed as a standalone treatment for advanced prostate cancer in a Phase 1b trial, ORIC-944 exhibited properties that suggest it could be a leading option in its category. These properties include a favorable safety profile, solid target engagement, and a clinical half-life of about 20 hours. Presently, ORIC-944 is under evaluation in combination with ERLEADA® (apalutamide) and NUBEQA® (darolutamide) as part of ongoing trials targeting mCRPC.

ORIC Pharmaceuticals is dedicated to enhancing patient outcomes by focusing on overcoming resistance mechanisms in cancer treatment. The company's pipeline includes ORIC-944 and ORIC-114. ORIC-114 is a brain-penetrant inhibitor that selectively targets genetic mutations such as EGFR exon 20, HER2 exon 20, and atypical EGFR mutations, with development efforts spanning various genetically defined cancers. Beyond these candidates, ORIC is committed to developing precision medicines that target other fundamental resistance mechanisms in cancer.

With offices located in South San Francisco and San Diego, California, ORIC Pharmaceuticals continues to push the boundaries in cancer research and therapy development.